Changes in ctDNA levels as an early indicator of outcomes in advanced NSCLC treated with TKI: Initial findings from a retrospective aggregate analysis of 8 clinical trials View PDF
Real-world response endpoints in patients with mNSCLC treated with chemotherapy across real-world datasets View PDF
2023 Impact of COVID-19 pandemic mitigation strategies on industry and NCI cancer treatment trials. Read more
2022 Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trials Read more
2022 2022 Annual Meeting: Supporting a Patient-Centric Approach to Dose Optimization in Oncology: The Essential Role of Patient-Reported Outcomes (PROs) View PDF
2022 2022 Annual Meeting: Impact of the COVID-19 Pandemic Mitigation Strategies on Cancer Clinical Trials View PDF
